CytoWatch™ QZ100 Monocyte Blocking Reagent

Ordering information

Price
Catalog Number
Unit Size
Quantity

Add to cart

Additional ordering information

Telephone	1-800-990-8053
Fax	1-800-609-2943
Email	sales@aatbio.com
International	See distributors
Bulk request	Inquire
Custom size	Inquire
Shipping	Standard overnight for United States, inquire for international

Physical properties

Solvent

Storage, safety and handling

H-phrase	H303, H313, H333
Hazard symbol	XN
Intended use	Research Use Only (RUO)
R-phrase	R20, R21, R22
Storage	Refrigerated (2-8 °C)
UNSPSC	12171501

Overview SDS Protocol

Example protocol

SAMPLE EXPERIMENTAL PROTOCOL

Cell Surface Staining Protocol for Flow Cytometry Analysis

Add 5 µL of CytoWatch™ QZ100 Monocyte Blocking Reagent to 100 µL of PBMC or whole blood.
Incubate for 5-10 minutes at room temperature or add primary antibodies immediately, and incubate at room temperature for 20 minutes.
Wash twice with cell staining buffer.
Resuspend cells in 0.5 mL of cell staining buffer.
Perform flow cytometric analysis.

Images

Figure 1. Human peripheral blood were either untreated (left) or treated with CytoWatch™ QZ100 Monocyte Blocking Reagent (right) and stained with CD3 (clone UCHT1) PE/Cyanine5.

References

View all 50 references: Citation Explorer

Synergistic reduction in albuminuria in type 2 diabetic mice by esaxerenone (CS-3150), a novel nonsteroidal selective mineralocorticoid receptor blocker, combined with an angiotensin II receptor blocker.
Authors: Arai, Kiyoshi and Morikawa, Yuka and Ubukata, Naoko and Sugimoto, Kotaro
Journal: Hypertension research : official journal of the Japanese Society of Hypertension (2020): 1204-1213

Prior β-blocker treatment decreases leukocyte responsiveness to injury.
Authors: Grisanti, Laurel A and de Lucia, Claudio and Thomas, Toby P and Stark, Aron and Strony, John T and Myers, Valerie D and Beretta, Remus and Yu, Daohai and Sardu, Celestino and Marfella, Raffaele and Gao, Erhe and Houser, Steven R and Koch, Walter J and Hamad, Eman A and Tilley, Douglas G
Journal: JCI insight (2019)

The Angiotensin Receptor Blocker Losartan Suppresses Growth of Pulmonary Metastases via AT1R-Independent Inhibition of CCR2 Signaling and Monocyte Recruitment.
Authors: Regan, Daniel P and Coy, Jonathan W and Chahal, Kirti Kandhwal and Chow, Lyndah and Kurihara, Jade N and Guth, Amanda M and Kufareva, Irina and Dow, Steven W
Journal: Journal of immunology (Baltimore, Md. : 1950) (2019): 3087-3102

Neprilysin Inhibitor-Angiotensin II Receptor Blocker Combination Therapy (Sacubitril/valsartan) Suppresses Atherosclerotic Plaque Formation and Inhibits Inflammation in Apolipoprotein E- Deficient Mice.
Authors: Zhang, Hui and Liu, Gangqiong and Zhou, Wenping and Zhang, Wenjing and Wang, Kai and Zhang, Jinying
Journal: Scientific reports (2019): 6509

Angiotensin II type 1 receptor blocker telmisartan induces apoptosis and autophagy in adult T-cell leukemia cells.
Authors: Kozako, Tomohiro and Soeda, Shuhei and Yoshimitsu, Makoto and Arima, Naomichi and Kuroki, Ayako and Hirata, Shinya and Tanaka, Hiroaki and Imakyure, Osamu and Tone, Nanako and Honda, Shin-Ichiro and Soeda, Shinji
Journal: FEBS open bio (2016): 442-60

The TLR-2/TLR-6 agonist macrophage-activating lipopeptide-2 augments human NK cell cytotoxicity when PGE2 production by monocytes is inhibited by a COX-2 blocker.
Authors: Müller, Christina and Tufa, Dejene M and Chatterjee, Debanjana and Mühlradt, Peter F and Schmidt, Reinhold E and Jacobs, Roland
Journal: Cancer immunology, immunotherapy : CII (2015): 1175-84

Renoprotective effects of angiotensin receptor blocker and stem cells in acute kidney injury: Involvement of inflammatory and apoptotic markers.
Authors: Sherif, Iman O and Al-Mutabagani, Laila A and Alnakhli, Anwar M and Sobh, Mohamed A and Mohammed, Hoda E
Journal: Experimental biology and medicine (Maywood, N.J.) (2015): 1572-9

Macrophage CD14 expression in human carotid plaques is associated with complicated lesions, correlates with thrombosis, and is reduced by angiotensin receptor blocker treatment.
Authors: Hermansson, Cecilia and Lundqvist, Annika and Magnusson, Lisa U and Ullström, Christina and Bergström, Göran and Hultén, Lillemor Mattsson
Journal: International immunopharmacology (2014): 318-23

Azilsartan, an angiotensin II type 1 receptor blocker, restores endothelial function by reducing vascular inflammation and by increasing the phosphorylation ratio Ser(1177)/Thr(497) of endothelial nitric oxide synthase in diabetic mice.
Authors: Matsumoto, Sachiko and Shimabukuro, Michio and Fukuda, Daiju and Soeki, Takeshi and Yamakawa, Ken and Masuzaki, Hiroaki and Sata, Masataka
Journal: Cardiovascular diabetology (2014): 30

Platelet activation in essential hypertension during exercise: pre- and post-treatment changes with an angiotensin II receptor blocker.
Authors: Gkaliagkousi, Eugenia and Gavriilaki, Eleni and Yiannaki, Efi and Markala, Dimitra and Papadopoulos, Nikolaos and Triantafyllou, Areti and Anyfanti, Panagiota and Petidis, Konstantinos and Garypidou, Vasileia and Doumas, Michael and Ferro, Albert and Douma, Stella
Journal: American journal of hypertension (2014): 571-8